Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

BACKGROUND: Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding to the type-2 vesicular monoamine transporter. A previous double blind study in Huntington disease (HD) demonstrated that TBZ effectively suppressed chorea, with a favorable short-term safety profile (Neuro...

Descripción completa

Detalles Bibliográficos
Autor principal: Frank, Samuel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804668/
https://www.ncbi.nlm.nih.gov/pubmed/20021666
http://dx.doi.org/10.1186/1471-2377-9-62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804668/
https://www.ncbi.nlm.nih.gov/pubmed/20021666
http://dx.doi.org/10.1186/1471-2377-9-62

Ejemplares similares